Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2025-12-25 @ 7:35 PM
Study NCT ID:
NCT07249632
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-01
First Post:
2025-11-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Sponsor:
RemeGen Co., Ltd.
Organization:
Study Overview
Official Title:
A Phase III Trial of Telitacicept in Patients With Ocular Myasthenia Gravis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America \[MGFA\] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) ocular score of ≥6 at screening and baseline.The study consists of a screening period of up to 6 weeks and a 24-week double-blind treatment period. The investigational product will be administered once weekly (QW) via subcutaneous injection. The dose for subjects aged ≥18 years is 240 mg. For adolescent subjects (12 to \<18 years), the dose is weight-based: subjects weighing 30 to 50 kg will receive 160 mg, and subjects weighing \>50 kg will receive 240 mg.The primary objective is to evaluate the efficacy of Telitacicept compared to placebo in treating OMG.The primary efficacy endpoint is the change from baseline in the MGII (PRO) ocular score at Week 24. Secondary endpoints include changes from baseline in other ocular and total scores from MGII, Myasthenia Gravis-Activities of Daily Living (MG-ADL), MG Clinical Absolute Score, and the 15-item Myasthenia Gravis Quality of Life Revised scale (MG-QOL15r). Safety and tolerability will be monitored throughout the study.
Detailed Description:
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of Telitacicept in subjects with Ocular Myasthenia Gravis (OMG). The study will be conducted at multiple centers.
The study duration for each subject will include a screening period of up to 6 weeks, followed by a 24-week double-blind treatment period.
Eligible subjects will be randomized in a 1:1 ratio to one of two treatment arms:
Arm 1: Telitacicept Arm 2: Placebo Randomization will be stratified by two factors: Acetylcholine Receptor (AChR) antibody status (positive vs. negative) and age (\<18 years vs. ≥18 years).
Primary Objective:
To evaluate the efficacy of Telitacicept compared to placebo in the treatment of subjects with Ocular Myasthenia Gravis.
Primary Endpoint:
Change from baseline in the Myasthenia Gravis Impairment Index (Patient-Reported Outcomes) \[MGII (PRO)\] ocular score at Week 24.
Study Population:
A total of approximately 120 subjects will be enrolled.
Intervention:
Subjects will receive either Telitacicept or a matching placebo, administered as a once-weekly (QW) subcutaneous injection for 24 weeks. The dose will be determined based on the subject's age and body weight at baseline:
Subjects aged 12 to \<18 years, with body weight 30 kg to 50 kg: 160 mg QW. Subjects aged 12 to \<18 years, with body weight \>50 kg: 240 mg QW. Subjects aged ≥18 years: 240 mg QW. The placebo will be identical in appearance to Telitacicept to maintain the blind.
Safety Assessments:
Safety and tolerability will be assessed through the monitoring and recording of adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, and regular laboratory tests (hematology, serum chemistry, urinalysis). An independent Data Monitoring Committee (DMC) will be established to monitor the safety of the trial.
The study duration for each subject will include a screening period of up to 6 weeks, followed by a 24-week double-blind treatment period.
Eligible subjects will be randomized in a 1:1 ratio to one of two treatment arms:
Arm 1: Telitacicept Arm 2: Placebo Randomization will be stratified by two factors: Acetylcholine Receptor (AChR) antibody status (positive vs. negative) and age (\<18 years vs. ≥18 years).
Primary Objective:
To evaluate the efficacy of Telitacicept compared to placebo in the treatment of subjects with Ocular Myasthenia Gravis.
Primary Endpoint:
Change from baseline in the Myasthenia Gravis Impairment Index (Patient-Reported Outcomes) \[MGII (PRO)\] ocular score at Week 24.
Study Population:
A total of approximately 120 subjects will be enrolled.
Intervention:
Subjects will receive either Telitacicept or a matching placebo, administered as a once-weekly (QW) subcutaneous injection for 24 weeks. The dose will be determined based on the subject's age and body weight at baseline:
Subjects aged 12 to \<18 years, with body weight 30 kg to 50 kg: 160 mg QW. Subjects aged 12 to \<18 years, with body weight \>50 kg: 240 mg QW. Subjects aged ≥18 years: 240 mg QW. The placebo will be identical in appearance to Telitacicept to maintain the blind.
Safety Assessments:
Safety and tolerability will be assessed through the monitoring and recording of adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, and regular laboratory tests (hematology, serum chemistry, urinalysis). An independent Data Monitoring Committee (DMC) will be established to monitor the safety of the trial.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: